MedTrace Logo

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

NCT02855086 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-03-31

Study results available
· View outcomes & findings →

Summary

This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is used.

Conditions

  • Brain Neoplasm
  • Malignant Glioma

Interventions

BIOLOGICAL

Cetuximab

Administered intravenously (IV)

DRUG

Cetuximab-IRDye 800CW

Administered intravenously (IV)

PROCEDURE

Tumor resection

Standard of care treatment

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eben Rosenthal

    lead OTHER

Principal Investigators

  • Gordon Li, MD · Stanford University

  • Eben Rosenthal, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2016-11-08
Completion
2016-11-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02855086 on ClinicalTrials.gov